HILS HILLSTREAM BIOPHARMA INC

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

  • Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts

BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held in person and virtually from September 11-13, 2023.

Event: H.C. Wainwright Presentation On-Demand

Date: September 11th, 2023

Time: 7:00am ET

Registration:

*Please note that Company presentation date and time are subject to change. Attendees may refer to the program agenda for more information. Once the presentation becomes available on-demand, registered attendees can submit their Q&As for the Company.

About Hillstream BioPharma Inc.

Hillstream BioPharma, Inc. is a biotechnology company developing a focused portfolio of therapeutic candidates targeting drug resistant and devastating cancers. The Company’s emerging immuno-oncology pipeline is led by HSB-3215, a novel anti-HER2/HER3 monoclonal antibody targeting unique epitopes with a novel mechanism of action. The erbB/HER family of cell surface proteins include well-known and validated drug targets including HER2 and HER3 found in multiple solid tumors, including breast, lung, GYN, endocrinological and CNS. Hillstream has a license agreement with OmniAb, Inc. to access the company’s antibody discovery technology platform against specified targets. For more information, please visit: .

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Hillstream’s expectations, strategy, plans or intentions. These forward-looking statements are based on Hillstream’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2022, and our periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Hillstream does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

“Picobody” is a trademark of Crystal Bioscience, Inc., a unit of OmniAb, Inc.

Investor Relations Contact

Email: 



EN
08/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on HILLSTREAM BIOPHARMA INC

 PRESS RELEASE

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clin...

Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting ...

 PRESS RELEASE

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global ...

Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conferen...

 PRESS RELEASE

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors...

Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215 Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on HER2/HER3 receptors Capitalizes on “Knob” biologics (PicobodiesTM) for tumor targeting, extends partnership to include validated target, HER3 IND filing for HSB-3215 planned in 2024 BRIDGEWATER, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”, the “Company”) today announced the expansion of i...

 PRESS RELEASE

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline ...

Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and proprietary novel bovine-derived biologic platform, PicoKnobTM, targeting undruggable epitopes on PD-1 and TROP2 Experienced biopharmaceutical executive joins as Chief Operating Officer to spearhead execution of ADC and biologic strategy ...

 PRESS RELEASE

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 a...

Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors Antibody CDRs against HER2 and HER3 Conformational Domain Bridging Epitopes can be used in multiple formats including bi- and tri-specific antibodies, antibody drug conjugates (ADCs), CAR-T and CAR-NKs BRIDGEWATER, N.J., July 06, 2...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch